Human gene therapy and congress.
Human gene therapy and congress.
复制标题
人类基因治疗和大会。
DOI：
10.1089/hum.1990.1.2-163
复制
发表时间：
1990
影响因子：
4.2
通讯作者：
R. Cook
中科院分区：
文献类型：
--
作者：
R. Cook
20 世纪 80 年代，国会是关于人类基因治疗的激烈辩论的场所。国会的兴趣主要是由神职人员和公共利益团体表达的对种系基因治疗的担忧引起的。最初的争论是由 1980 年马丁·克莱恩 (Martin Cline) 的不幸遭遇引发的，并于 1983 年因参议员马克·哈特菲尔德 (Mark Hatfield) 发起的反对生殖系干预的国会决议而重新点燃。关于基因治疗的第一次听证会于 1982 年 11 月在总统委员会报告《剪接生命》发布后举行，随后由国会议员小阿尔伯特·戈尔 (Albert Gore, Jr.) 主持的众议院小组委员会举行。戈尔代表随后要求提供一份关于基因治疗的报告，该报告由技术评估办公室于 1984 年 12 月发布。他还发起了建立生物医学伦理委员会和生物医学伦理咨询委员会的立法，这是国会重建联邦生物医学伦理委员会的失败尝试。生物伦理委员会。人类遗传学进步（包括基因治疗）的影响将成为首要讨论的主题之一。国会没有通过影响基因治疗研究或临床试验的实质性立法，但主要充当国家辩论的舞台。如果考虑进行种系基因治疗，国会将面临艰难的选择，但很可能不会采取任何行动来阻止看似安全且旨在为特定个体带来临床益处的试验。
Congress was the scene of conspicuous debate about human gene therapy during the 1980s. Congressional interest was sparked primarily by concerns about germ-line gene therapy expressed by clerics and public interest groups. The initial debate was provoked by Martin Cline's misadventures in 1980 and rekindled in 1983 by congressional resolution against germ-line intervention sponsored by Senator Mark Hatfield. The first hearing on gene therapy was held upon the release of the President's Commission report Splicing Life, in November, 1982, before a House subcommittee chaired by Congressman Albert Gore, Jr. Representative Gore later requested a report on gene therapy, which was released by the Office of Technology Assessment in December, 1984. He also sponsored the legislation that established the Biomedical Ethics Board and Biomedical Ethics Advisory Committee, Congress's abortive attempt to reestablish a federal bioethics commission. Implications of advances in human genetics, including gene therapy, were to be among the first topics addressed. Congress passed no substantive legislation affecting gene therapy research or clinical trials, but served principally as a national theater for debate. If and when germ-line gene therapy is contemplated, Congress will be faced with difficult choices, but will likely take no action to block trials that appear safe and are intended to produce clinical benefit for particular individuals.